Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRI) Equity Average (2021 - 2025)

Historic Equity Average for Biofrontera (BFRI) over the last 5 years, with Q3 2025 value amounting to -$3.6 million.

  • Biofrontera's Equity Average fell 14409.1% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year decrease of 14409.1%. This contributed to the annual value of $4.6 million for FY2024, which is 6782.11% down from last year.
  • Latest data reveals that Biofrontera reported Equity Average of -$3.6 million as of Q3 2025, which was down 14409.1% from -$2.1 million recorded in Q2 2025.
  • Biofrontera's Equity Average's 5-year high stood at $23.2 million during Q4 2022, with a 5-year trough of -$3.6 million in Q3 2025.
  • Over the past 5 years, Biofrontera's median Equity Average value was $3.9 million (recorded in 2023), while the average stood at $7.7 million.
  • The largest annual percentage gain for Biofrontera's Equity Average in the last 5 years was 89181.38% (2025), contrasted with its biggest fall of 17585.08% (2025).
  • Over the past 5 years, Biofrontera's Equity Average (Quarter) stood at -$3.0 million in 2021, then surged by 869.17% to $23.2 million in 2022, then crashed by 87.45% to $2.9 million in 2023, then skyrocketed by 70.86% to $5.0 million in 2024, then plummeted by 172.76% to -$3.6 million in 2025.
  • Its Equity Average was -$3.6 million in Q3 2025, compared to -$2.1 million in Q2 2025 and $2.5 million in Q1 2025.